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ABSTRACT
Breast cancer (BC) is a heterogeneous disease, including different subtypes 
having diverse incidence, drug-sensitivity and survival rates. In particular, claudin-
low and basal-like BC have mesenchymal features with a dismal prognosis. 
Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety 
of cancers. Despite its potential relevance in cancer diagnostics and therapeutics, the 
presence and role of GD2 require further investigation, especially in BC. Therefore, we 
evaluated GD2 expression in a cohort of BC patients and its correlation with clinical-
pathological features.
Sixty-three patients with BC who underwent surgery without prior chemo- and/
or radiotherapy between 2001 and 2014 were considered. Cancer specimens were 
analyzed by immunohistochemistry and GD2-staining was expressed according to the 
percentage of positive cells and by a semi-quantitative scoring system. 
Patient characteristics were heterogeneous by age at diagnosis, histotype, 
grading, tumor size, Ki-67 and receptor-status. GD2 staining revealed positive cancer 
cells in 59% of patients. Among them, 26 cases (41%) were labeled with score 1+ and 
11 (18%) with score 2+. Notably, the majority of metaplastic carcinoma specimens 
stained positive for GD2. The univariate regression logistic analysis revealed a 
significant association of GD2 with triple-receptor negative phenotype and older age 
(> 78) at diagnosis. 
We demonstrate for the first time that GD2 is highly prevalent in a cohort of 
BC patients clustering on very aggressive BC subtypes, such as triple-negative and 
metaplastic variants.  
INTRODUCTION
Breast cancer (BC) survival rates have increased 
in the last decades, thanks to intense screening programs 
and to increasingly targeted and effective therapeutics [1]. 
BC is a heterogeneous disease with different patterns of 
incidence, survival and drug-sensitivity. In the last few 
years gene expression profiling identified five molecular 
intrinsic subtypes. In the early 2000 luminal A, luminal 
B, Her2-enriched and basal-like BC were described [2–4]. 
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Later, Prat et al. defined a claudin-low subtype, 
characterized by low expression of genes involved in cell-
cell adhesion, high mesenchymal features and with stem 
cell features [5]. While the luminal A and B can be mostly 
identified by estrogen and progesterone receptors and the 
Her2-enriched subtypes by a HER2 positivity, the highly 
aggressive basal-like and claudin-low tumors are included 
in the triple negative BC (TNBC) phenotype and still 
lack of more defined markers [4, 5]. Moreover Lehmann 
et al. identified six TNBC subtypes displaying unique 
gene expression (basal-like 1 and 2, immunomodulatory, 
mesenchymal, mesenchymal stem-like and luminal 
androgen receptor) capable to inform therapy selection [6].
In this perspective we focused on disialoganglioside 
GD2, a surface antigen, primarily expressed in the nervous 
system and skin melanocytes as well as in the stromal 
component of other normal tissues [7]. More recently, we 
have identified GD2 as a surface marker of mesenchymal 
stromal cells (MSC), adult progenitors that can be 
isolated from different tissues and ex vivo expanded [8]. 
In cancer, disialoganglioside GD2 is typically expressed in 
neuroectodermal tumors, such as neuroblastoma, glioma 
and melanoma [9, 10], but it can also be found in a variety 
of sarcomas [11–13]. 
Battula et al. identified GD2 as a suitable marker for 
BC stem cells (BCSC) and its expression was described 
in BC cell lines as well as in a few histological samples 
[14]. Moreover, the inhibition of GD3 synthase, the 
critical enzyme involved in GD2 synthesis, has been 
shown to prevent metastasis in in-vivo mouse models, 
to inhibit epithelial-mesenchymal transition (EMT) and 
to compromise mesenchymal characteristics of claudin-
low BC cell lines [14–16].  Despite the relevance of these 
data, the possible role of GD2 as a BC biomarker and 
therapeutic target still requires in-depth investigations. 
For this reason, we sought to report for the first time 
histological evidences of the GD2 expression pattern 
in a heterogeneous cohort of BC samples, highlighting 
the peculiar tendency of this antigen to correlate with a 
mesenchymal-like phenotype and significantly with the 
triple negative phenotype.
RESULTS
Patients
Clinical-pathological characteristics of the sixty-three 
patients included in the study are shown in Table 1. Average 
age at diagnosis was 67 ± 15 years old. The most represented 
histological types were invasive ductal carcinoma 
(IDC) not otherwise specified (NOS) (37/63; 59%), 
metaplastic carcinoma (14/63; 22%) and invasive lobular 
carcinoma (ILC) (7/63; 11%). The other cases included 
mixed carcinoma (IDC + invasive lobular carcinoma) 
(2/63; 3%), apocrine ductal carcinoma (2/63; 3%) 
and one sample of carcinosarcoma (2%). Concerning the 
histological grade, in most cases (49/63; 78%) tumors were 
G3; the other cases (14/63; 22%) were G2. 
Tumor size ranged from 0,7 cm to 10 cm, with a 
mean of 3,2 ±  2,4 cm with 42 (67 %) patients having  a 
Ki-67 expression greater than 20%. Twenty-seven samples 
(43%) were pT1, 22 (35%) were pT2, 11 (17 %) were 
pT3 and three samples were pT4 (5%). Forty patients 
(63%) were both hormone receptors and HER2 negative 
(TNBC). Eighteen cases (29%) were hormone receptors 
positive, but did not over-expressed HER2. Five samples 
over-expressed HER2: 3 (5%) were also hormone receptor 
positive, 2 (3%) were ER/PR negative.
GD2 marks BC cells clustering on TNBC
The evaluation of GD2 IHC staining in the sixty-
three BC specimens revealed an antigen expression in 37 
cases (59%). 
According to our GD2 semi-quantitative scoring 
system (Figure 1), 26 cases (41%) were negative (score 0); 
among the GD2 positive specimens (37/63; 59%), 26 
(41%) were identified with score 1+ and 11 (18%) with 
score 2+. The percentage of positive cells in the GD2 
expressing specimens was extremely variable, ranging 
from 3% to 100%, with a mean of 52% ± 30%. Having 
observed this positivity, we focused on the staining 
pattern. GD2 was mainly expressed in the cytoplasm 
(Figure 2A). Additionally, BC cells showed a GD2 staining 
reinforcement on the cell membrane (Figure 2B). Of note 
stroma and normal glandular ducts were apparently not 
stained, confirming the specificity of staining on BC cells 
(Figure 2C). 
After observing the relevance of the staining, we 
then correlated the GD2 status with clinical-pathological 
parameters as shown in Table 2. No statistical correlation 
was found between GD2 and the considered variables 
according to Student’s t-test, χ2 test and Fisher’s 
exact test.  However, the samples from metaplastic 
sarcomatoid carcinoma retained the highest staining, with 
GD2 expression mostly related to spindle cells versus 
epithelioid elements (Figure 2D). 
To further investigate a possible association of 
GD2 with any of the clinical-pathological parameters 
we performed both multivariate and univariate logistic 
regression analyses. While multivariate analysis showed 
no significant correlations (including Ki-67 expression), 
the univariate analysis (Table 3) indicated that in GD2 
positive specimens the possibility of being TNBC 
was significantly higher than being ER/PR +/HER2– 
(OR = 3.26; p = 0.04; 95% CI [1.03–10.37]), suggesting 
how GD2 may represent a novel marker capable to 
identify a still elusive BC subtype. We also compared 
the GD2 expression in relationship with age, revealing 
a significant correlation within the older patients range 
(> 78) with significant higher GD2 expression (OR = 3.66; 
p = 0.04; 95% CI [1.05–12.79]). 
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DISCUSSION
To the best of our knowledge, in this report we 
describe the expression of GD2 in the largest cohort of 
BC so far reported. By the introduction of a new semi-
quantitative IHC scoring system, we provide evidence 
that the majority of the analyzed samples resulted GD2 
positive.
Disialoganglioside GD2 is synthesized in the 
endoplasmatic reticulum and Golgi’s apparatus by the 
enzyme GD3 synthase. The antigen is then transferred 
on the outside layer of the plasma membrane. On the 
cell surface, GD2 is involved in cell-to-cell adhesion 
and signal transduction, playing a crucial role both in 
physiological (e.g. embryogenesis) and in pathological 
processes, such as cancer, by driving proliferation, 
neoangiogenesis, immune-escape and invasion. [17–19]. 
GD2 represents a typical marker of neuroectodermic 
tumors. Neuroblastoma shows a constant expression of 
this ganglioside, which has been exploited as a therapeutic 
target for monoclonal antibody and cellular therapy [7, 
20–22]. GD2 was also found in tissue sections and cell 
lines of other neuroectodermic tumors, such as skin and 
uveal melanoma, small cell lung cancer and glial tumors 
[9, 10, 23–25]. In addition, GD2 labels soft tissue and 
bone sarcomas [11–13, 26, 27]. In normal conditions, 
although at lower levels, it is expressed in nervous tissues 
and in adult progenitors [8, 20], confirming its role as both 
neuroectodermal and mesenchymal marker. 
Originally GD2 expression was investigated in 
BC by Battula et al., who identified this ganglioside in 
BC cell lines, showing positive levels between 0,1–18% 
with the highest expression curiously related to a basal-
like phenotype [14]. The authors additionally focused on 
BCSC reporting GD2 as their putative biomarker. BCSC 
are a rare subset of cells within the tumor exhibiting a 
high tumorigenic potential [28–30]. BCSC have also been 
related to the EMT and to MSC, since the induction of EMT 
in mammary cells results in the acquisition of features that 
are typical of both BCSC and MSC [28, 29, 31, 32]. These 
findings were also confirmed by Liang et al. focusing on the 
expression profile of glycosphingolipids in human BCSC 
[15]. The role of GD2 as a marker of EMT and BCSC in 
BC was also indirectly demonstrated through the inhibition 
of GD3 synthase, which compromised the initiation 
and maintenance of EMT, as well as the mesenchymal 
characteristics of claudin-low BC cell lines SUM159 and 
MDA-MB-231 [16].
Table 1: Patient and tumor characteristics
Clinical-pathological parameters N°/63 (%) 
Median age at diagnosis ± SD 67 ± 15 yrs
Histological Type
IDC
ILC
Mixed (IDC+ILC)
Metaplastic
Apocrine
Carcinosarcoma
37 (59)
7 (11)
2 (3)
14 (22)
2 (3)
1 (2)
Histological Grade
G2
G3
14 (22)
49 (78)
Tumor Size – pT 
pT1 
pT2 
pT3 
pT4
27 (43)
22 (35)
11 (17)
3 (5)
Hormone Receptor and HER2 status
ER/PR +, HER2 –
ER/PR - , HER2 +
ER/PR +, HER2 + 
TNBC 
18 (29)
2 (3)
3 (5)
40 (63)
Ki-67
< 20%
> 20%
21 (33)
42 (67)
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; ER = estrogen receptor; PR = progesteron receptor; 
TNBC = triple-negative breast cancer
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The immunohistochemical analysis of GD2 
expression in our 63 specimens showed a positive staining 
in 59% of the cases. Battula et al. considered 12 patients 
with a variety of BC histotypes and, considering as an 
arbitrary cut-off of 5%, their positivity level seems similar 
(58.3%) to the one here reported in a greater BC cohort. 
Their positive cells ranged from 0.5 to 37.9% and, very 
interestingly, the highest positivity is described in the two 
metastatic specimens peaking in the only TNBC specimen 
included in the study [14]. No correlation analyses with 
clinical-pathological features were performed in that study, 
presumably due to the low number of included patients.  
In this research we focused on GD2 expression 
pattern, originally showing a cytoplasmatic along with a 
membrane staining by IHC. While GD2 has been reported 
to be predominately exposed on the cell membrane, GD2 
pattern in BC is coherent with results reported in other 
neuroectodermal and mesenchymal neoplasms [12, 20, 27] 
and it can be due to the biosynthetic pathway of the 
ganglioside. 
Our cohort of BC was heterogeneous by age at 
diagnosis, histotype, grading, Ki-67, tumor size and 
receptor phenotype. Student’s t-test, Fisher’s exact test 
and multivariate logistic regression analysis did not 
demonstrate any statistically significant correlation 
between GD2 expression and any of these variables, 
including Ki-67. The age appeared as a discriminant factor 
with older patients having a greater GD2 level, however 
this finding may be biased by the fact that most of OUR 
metasplastic BC samples falls into an advanced age. In this 
sense a larger patient cohort shall be requested to further 
validate these findings. Interestingly, the univariate logistic 
regression analysis showed a statistically significant 
correlation of ganglioside GD2 with triple-negative BC 
in comparison to ER/PR +/HER2 –, thus confirming the 
preliminary data in a single case of TNBC reported [14]. 
A similar trend was found with metaplastic carcinomas 
compared to IDC, although not statistically significant.
Some considerations have to be shared about GD2 
expression pattern according to the histotype. Despite 
the limited number of patients included in the study, the 
majority of metaplastic breast carcinoma samples were 
GD2 positive, showing the strongest staining in their 
spindle-like elements and not in their epithelial-like 
component. The expression of BCSC-related antigens 
and EMT markers (Zeb-1, E-cadherin) has already been 
demonstrated in metaplastic BC histological specimens, 
where the positivity was mostly related to the non-
Figure 1: GD2 scoring system. Representative areas of the different GD2 staining intensities are shown at greater magnification in 
insets. Scale bar: 50 µm. 
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Figure 2: Pattern of GD2 localization in breast cancer. Cytoplasmatic (A; arrow) and membrane (B; arrow head) positivity for 
GD2 in breast cancer specimens. Few GD2 positive cells are visible within negative stroma (C). Strong GD2 staining in spindle cells in a 
metaplastic sarcomatoid breast cancer section (D) Scale bar: 20 µm (A, B), 50 µm (C, D). 
Table 2: Correlation between GD2 expression and clinical-pathological parameters
Clinical-pathological 
parameters
GD2 negative 
N° (%)
GD2 positive 
N° (%) Total p value
Patients 26 (41) 37 (59) 63
Median age at diagnosis ± SD 63 ± 14 70 ± 15 0.058
Histological Type
IDC
ILC
Mixed (IDC + ILC)
Metaplastic
Apocrine
Carcinosarcoma
19 (51)
4 (57)
0 (0)
3 (21)
0 (0)
0 (0)
18 (49)
3 (43)
2 (100)
11 (79)
2 (100)
1 (100)
37 
7 
2 
14 
2 
1 
0.137
Histological Grade
G2
G3
8 (57)
18 (37)
6 (43)
31 (63)
14
49 
0.223
Tumor Size – pT 
pT1 
pT2
pT3
pT4 
13 (48)
9 (41) 
4 (36)
0 (0)
14 (52)
13 (59)
7 (64)
3 (100)
27 
22
11
3 
0.433
Hormone Receptor and HER2 
status
ER/PR +, HER2 -
ER/PR – , HER2 +
ER/PR +, HER2 +
TNBC
11 (61)
1 (50)
1 (33)
13 (33)
7 (39)
1 (50)
2 (67)
27 (67)
18 
2 
3 
40 
0.158
Ki-67
< 20%
> 20%
11 (52)
15 (36)
10 (48)
27 (64)
21
42
0.205
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; ER = estrogen receptor; PR = progesteron receptor; 
TNBC = triple-negative breast cancer.
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epithelial/mesenchymal part of these tumors [33]. BCSC 
biomarkers, including GD2 in association with ALDH, 
were also described in a cohort of phyllodes tumors, a 
rare subtype of breast neoplasm that shows some affinities 
with metaplastic tumors [34]. We can speculate that 
GD2 expression in the BC specimens analyzed in this 
study might be related to BCSC and to the activation of 
the process of EMT. We also suggest that GD2-positive 
specimens contain cells that are undergoing EMT and 
the association of GD2 with the triple-receptor negative 
phenotype along with the constant expression of this 
antigen in the metaplastic BC specimens seems to 
corroborate this. These neoplasms are in fact characterized 
by a structural mesenchymal component [33, 35] and 
might exhibit a more constitutive and regular expression 
of BCSC and EMT biomarkers, including GD2. 
This investigation retains limitations mostly due to 
the small sample size and to the sampling method. However, 
the study had an explorative intent and was performed since 
no consistent data on GD2 and its correlation with clinical-
pathological parameters in BC have been previously 
reported. Another limitation of the study is the lack of an 
external validation of GD2 IHC staining procedures and 
scoring system. In this case a relevant effort was dedicated 
to identify an anti-GD2 antibody capable to generate 
consistent results on paraffin embedded BC specimens. 
The proposed scoring system has now to be challenged 
in a larger cohort of patients in the effort to generate a 
standardized method for GD2 immunohistochemical 
evaluation in BC and, possibly, in other cancer types. 
To conclude, GD2 staining was for the first time 
described in a heterogeneous cohort of BC specimens, 
showing a possible correlation with histotypes strongly 
associated with EMT.   Although studies are now needed to 
consolidate these results, GD2 appears as a new biomarker 
in BC, in particular for the TNBC variants, which are still 
orphans of specific markers for diagnostics and possible 
targeted therapies.
Table 3: Univariate logistic regression analysis
Clinical-pathological parameters OR P [95% CI]
Age at diagnosis (yrs)
0–69
70–78
> 78 
reference
3.27
3.66
0.09
0.04
[0.83–12.81]
[1.05–12.79]
Histological Type
IDC
Metaplastic
ILC
Mixed (ILC+IDC)
Apocrine
Carcinosarcoma
reference
3.87
0.79
1
1
1
0.06
0.78
na
na
na
[0.92–16.17]
[0.15–4.04]
na
na
na
Histological Grade
G2
G3
reference
2.23 0.18 [0.69–7.68]
Tumor Size – pT
pT1
pT2
pT3
pT4
reference
1.34
1.62
1
0.61
0.51
na
[0.43–4.18]
[0.38–6.87]
na
Hormone Receptor and  HER2 
status
ER/PR +, HER2 –
TNBC
ER/PR -, HER2+
ER/PR+, HER2+
reference
3.26
1.57
3.14
0.04
0.76
0.38
[1.03–10.37]
[0.08–29.41]
[0.24–41.51]
Ki-67
< 20%
> 20%
reference
1.98 0.21 [0.68–5.74]
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; ER = estrogen receptor; PR = progesteron receptor; 
TNBC = triple-negative breast cancer.
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MATERIALS AND METHODS
Patients and specimens 
The archive of the Pathology Division of Modena 
University Hospital and Padua University Hospital 
was searched to identify sixty-three female patients 
diagnosed with infiltrating BC from 2001 to 2014, with 
available samples from primary tumors (mastectomy or 
quadrantectomy specimens). Clinical-pathological data 
included age at diagnosis, tumor size (T), histological 
type, histological grade (according to the Nottingham 
Grading System [36]), Ki-67, Estrogen receptor, 
Progesterone receptor and HER2 status as described in 
the pathological report and confirmed by the pathologist’s 
review. As stated in the latest ASCO/CAP guidelines 
[37], hormone receptors were considered positive when 
≥ 1% of cancer cells stained by immunohistochemistry 
(IHC). HER2 was assessed as over-expressed in those 
cases showing ISH positive, or IHC score 3+, or IHC 
score 2+ and ISH positive (ASCO/CAP guidelines 2013 
[38]). Prior treatment with chemotherapy or radiotherapy 
was an exclusion criterion. Written informed consent was 
obtained from alive patients. According to these inclusion 
and exclusion criteria, we selected a cohort of 51 BC 
specimens for a preliminary evaluation of GD2 staining. 
After observing a relevant expression of the antigen in 
three samples of metaplastic BC included in this initial 
dataset, we enriched our population with 12 more cases 
of metaplastic BC, so that a final cohort of 63 patients 
was considered. The study protocol was approved by the 
Ethical Committees of Modena and Padua.  
Immunohistochemistry 
Preliminary IHC tests with different anti-GD2 
antibodies (Table 4) were performed on neuroblastoma 
and melanoma histological specimens and cell lines 
(data not shown), in order to set up the procedure. After 
extensive testing, the selected antibody was an anti-GD2 
rabbit polyclonal antibody (1:200 dilution; Matreya LLC, 
Pleasant Gap, PA). Formalin-fixed, paraffin-embedded 
4-μm-thick tissue sections from BC specimens were 
transferred to microscope slides. Sections were dried 
overnight at 40°C; after heat-induced antigen retrieval, 
slides were incubated with the anti-GD2 antibody for 12 
minutes at 37°C, using an automatic immunohistochemical 
staining device (Benchmark XT; Ventana Medical 
Systems, Tucson, AZ). The reaction was subsequently 
detected with the appropriate reagent from Kit Ventana 
DAB (Ventana Medical Systems, Tucson, AZ). Lastly, 
sections were counterstained with Harris hematoxylin and 
analyzed by standard light microscope (Axio Imager M2 - 
Zeiss) with Plan-Apochromat 20X/0.8, EC Plan-Neofluar 
40X/0.75 and EC Plan-Neofluar 63X/1.25-Oil objectives. 
Slides stained with no primary antibody were used as 
negative control. Photomicrographs were acquired with 
Axiocam 506 color camera (software ZEN pro - Zeiss).
Scoring 
Any distinct positive IHC staining of BC cells within 
the samples was regarded as positive GD2 expression, with 
a modified scoring system from Ziebarth et al. there applied 
in uterine leiomyosarcoma [27]. With the aim to properly 
quantify GD2 expression in the considered specimens, we 
established a semi-quantitative scoring system, based on 
three different levels of staining intensity:  0 (negative), 
1+ (low positivity), 2+ (high positivity). In those samples 
having either 1+ or 2+ score, the portion of GD2 positive 
tumor cells was expressed as percentage (%). 
Statistical analysis 
The primary study endpoint was the evaluation 
of GD2 expression and its correlation with clinical-
pathological features in a cohort of BC patients. Given 
the explorative aim of this investigation, no sample size 
calculation was performed. Relationships between the BC 
clinical-pathological parameters and GD2 expression were 
analyzed using χ2 test and Fisher’s exact test for categorical 
variables; Student’s t-test was used for continuous 
variables. Furthermore, univariate and multivariate logistic 
regression analyses were performed. The significance level 
was set at p < 0.05. Data were analyzed using STATA13 
(StataCorp. 2011. Stata: Release 12. Statistical Software. 
College Station, TX: StataCorp LP).
Abbreviations
BC: breast cancer; TNBC: triple-negative breast 
cancer; MSC: mesenchymal stromal cells; BCSC: 
Table 4: Anti-GD2 antibodies tested for immunohistochemistry
Name Type Source Dilution Company
Anti-ganglioside GD2 Polyclonal, isotype IgG/IgM Rabbit 1:200 Matreya LLC
Anti-ganglioside GD2 
antibody (2Q549) Monoclonal, IgG2a Mouse 1:10; 1:40 Abcam
Ganglioside GD2 (14G2a) Monoclonal, IgG2a Mouse 1:25; 1:50
Santa Cruz 
Biotechnology
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breast cancer stem cells; EMT: epithelial-mesenchymal 
transition; IHC: immunohistochemistry; IDC: invasive 
ductal carcinoma; NOS: not otherwise specified; ILC: 
invasive lobular carcinoma.
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